Document is current

Article History

Received: 28 September 2022

Accepted: 20 January 2023

First Online: 1 February 2023

Competing interests

: PX has received personal fees from MSD and OMT, outside the submitted work. OG, NBe, FT and NM have nothing to declare. CAE received speaking fees from MSD, outside the submitted work. BE received travel fees, consulting fees, speaking fees, and/or honoraria from Actelion, MSD, Bayer and OMT (less than $10,000 each). SH has received personal fees from Bayer, MSD, Actelion and GSK, outside the submitted work. AMM has received personal fees from Bayer, MSD and Boehringer-Ingelheim outside the submitted work. CN has received consulting fees, speaking fees, and/or honoraria from Actelion, MSD, Boehringer, Novartis, Bayer, and AstraZeneca (less than $10,000 each). NBl has received consulting fees, speaker fees, and/or honoraria from AbbVie, BMS, Pfizer, Roche, Novartis, UCB, Janssen-Cilag, Novartis, SOBI, Actelion outside the submitted work. HML has received consulting fees, speaking fees, and/or honoraria from AbbVie, BMS, Pfizer, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly (less than $10,000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, and Thermo Fisher. EG has received grants and personal fees from Actelion, Bayer AG, and MSD; grants from GSK, Novartis, and United Therapeutics; and personal fees from SCOPE, OrPha Swiss GmbH, and Zurich Heart House (less than $10,000 each).